Sagimet Biosciences Inc.
SGMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from. Valued at $680.0M, SGMT is a small-cap name in its sector. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Market Cap
$680.0M
Beta
3.49
P/E (TTM)
—
P/E (Fwd)
-7.94
EPS (TTM)
$-1.26
EPS (Fwd)
$-1.38
ROE
-24.4%
ROA
-16.4%
Cash
$240.1M
Total Debt
$1.9M
Free CF
-$27.8M
52W Change
58.8%
Annual Financials
Cash vs Debt
Where SGMT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SGMT finished 58.13% above its 150-day moving average ($6.95) and 61.62% above its 200-day moving average ($6.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGMT overbought or oversold?
At the September 3, 2026 close, SGMT's RSI(14) was 71.2, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $240.1M in cash comfortably exceeding the $1.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$27.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -24.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Sagimet Biosciences Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, SGMT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sagimet Biosciences Inc. and its sector.